靶向B7-H3的CAR-T细胞特异性识别并杀伤横纹肌肉瘤

Objective: To develop chimeric antigen receptor-modified T cells (CAR-T) targeting B7-H3 against malignant rhabdomyosarcoma, and based on this, to further construct B7-H3-CAR-T that can co-secrete PD-1 nanobody. Additionally, to investigate in vitro the anti-tumor efficaciousness of both types of CAR-T against rhabdomyosarcoma. Methods: B7-H3-CAR-T and B7-H3-PD-1-CAR-T cells were constructed by lentiviral transfection. Antibody production was measured by flow cytometry and protein blotting, and the in vitro antitumor effects of CAR-T were then investigated by real time cellular analysis and flow cytometry. Results: B7-H3-PD-1-CAR-T could continuously secrete PD-1 nanobody, and both CAR-T cells targeting B7-H3 could be specifically activated and expanded upon antigen stimulation, and both exhibited significant cytotoxicity against the rhabdomyosarcoma cell line A204, while maintaining good sustained killing ability.Conclusion: CAR-T cells targeting B7-H3 were able to specifically recognize and kill malignant rhabdomyosarcoma.